AN2 Therapeutics, Inc. (ANTX)
↓ Download CSVKey ratios (FY2025)
-66.3%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Operating Income | -$38.11M | -$56.79M | -$69.64M | -$42.26M | -$21.57M | — |
| Net Income | -$35.17M | -$51.32M | -$64.73M | -$40.96M | -$21.54M | — |
| EPS (Diluted) | $-1.16 | $-1.72 | $-2.74 | $-2.79 | $-10.64 | — |
| Total Assets | $61.95M | $92.09M | $138.74M | $102.56M | $65.32M | — |
| Total Liabilities | $8.89M | $10.24M | $14.04M | $7.19M | $3.41M | — |
| Shareholders' Equity | $53.06M | $81.85M | $124.70M | $95.37M | -$47.41M | -$20.32M |
| Cash & Equivalents | $19.94M | $21.35M | $15.65M | $27.22M | $12.10M | — |
| Operating Cash Flow | -$29.83M | -$49.26M | -$53.29M | -$33.46M | -$20.48M | — |
| Shares Outstanding | 27.41M | 29.92M | 29.74M | 19.40M | 2.73M | — |